# Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

> **NCT02894684** · PHASE4 · COMPLETED · sponsor: **Liverpool Heart and Chest Hospital NHS Foundation Trust** · enrollment: 16 (actual)

## Conditions studied

- Cystic Fibrosis
- Infection
- Pseudomonas

## Interventions

- **DRUG:** Aztreonam
- **DRUG:** Standard Care

## Key facts

- **NCT ID:** NCT02894684
- **Lead sponsor:** Liverpool Heart and Chest Hospital NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2019-02
- **Final completion:** 2019-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02894684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02894684, "Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02894684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*